News
BridgeBio Oncology Therapeutics
BBOT · NASDAQ
$2.72−$0.13 (−4.56%)TodayMarket closed ·
Prev close $2.85
Latest news
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- Press releaseGlobe Newswire
BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers
- Press releaseGlobe Newswire
BBOT to Participate in Upcoming Investor Healthcare Conferences
- Press releaseGlobe Newswire
BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
- NewsAvi Kapoor
Penguin Solutions, Beazer Homes, Alibaba And Other Big Stocks Moving Higher On Wednesday
- Press releaseGlobe Newswire
BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- Press releaseGlobe Newswire
BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026
- Press releaseGlobe Newswire
BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman
- Press releaseGlobe Newswire
BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026
- Press releaseGlobe Newswire
BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma
- Press releaseGlobe Newswire
BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor
- Press releaseGlobe Newswire
BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
- Press releaseGlobe Newswire
BBOT to Participate in Upcoming Investor Healthcare Conferences
- Press releaseGlobe Newswire
BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs
- Press releaseGlobe Newswire
BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference
- Press releaseGlobe Newswire
BBOT to Participate in Upcoming December Investor Healthcare Conferences
- Press releaseGlobe Newswire
BBOT to Participate in the Jefferies Global Healthcare Conference in London
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.